Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
1. Patients must have biopsy-proven locally-advanced, metastatic or recurrent adenocarcinoma of the biliary ducts or gallbladder.~2. Patients must have measurable disease.~3. Patients must be 18 years or older.~4. Patients must have a NCI CTC Performance Status of 0-2.~5. Patients must have a life expectancy of \>= 3 months.~6. Patients must not have any prior chemotherapy for metastatic disease. Prior adjuvant radiation therapy and chemotherapy with 5FU and/or gemcitabine is allowed.~7. At least 3 weeks should have elapsed since any surgery requiring general anesthesia.~8. Patients must have no prior malignancies except for basal or squamous skin cancers, cervical carcinoma-in-situ.~9. Pregnant patients are not eligible. Non-pregnant status will be determined in all women of childbearing potential. All patients will be required to use an effective means of contraception if sexually active during therapy.~10. Initial Required Laboratory Values:~    * 1. Absolute neutrophil count \>= 1,500/mm3, platelet count \>= 100,000/mm3, and hemoglobin \>= 9 g/dL.~   * 2. Serum creatinine should be \<= 2 mg/dL.~   * 3. Serum bilirubin should be \<= 3.0 mg/dL (biliary stents allowed).~   * 4. Serum transaminases should be \<= 5-fold the institutional upper limits.~11. Patients must not have any co-existing severe medical illnesses, such as unstable angina, uncontrolled diabetes mellitus, uncontrolled arrhythmia or uncontrolled infection.~12. Patients must be able to sign an informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Carboplatin (Type: EXPERIMENTAL): Gemcitabine 1000 mg/m2 IV for 30 minutes on days 1 and 8 of 21 day cycle. Maximum of 9 cycles.~Carboplatin AUC 5 IV for 1 hour on day 1 of 21 day cycle. Maximum of 9 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).